NCT04384614 (CONNAITRE) is a clinical trial of Test PCR in Covid 19, sponsored by Direction des Soins de Santé de Base.

Who is sponsoring NCT04384614?

NCT04384614 is sponsored by Direction des Soins de Santé de Base.

What drugs are being tested in NCT04384614?

Interventions in NCT04384614: Test PCR, TDR, Clinical Examination.

What condition does NCT04384614 study?

NCT04384614 studies Covid 19, BCG Vaccination.

Is NCT04384614 still recruiting?

NCT04384614 is currently withdrawn. Last updated 27 August 2020.

Last reviewed 2020-08-27 · How we verify

NCT04384614: CONNAITRE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study

Withdrawn Last updated 27 August 2020

What this trial tests

trial testing Test PCR in Covid 19. Withdrawn.

Timeline

15 May 2020

Primary endpoint
15 July 2020

15 July 2020

Quick facts

Lead sponsor	Direction des Soins de Santé de Base
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	15 May 2020
Primary completion	15 July 2020
Estimated completion	15 July 2020
Sites	1 location across Tunisia

Drugs / interventions tested

Test PCR
TDR
Clinical Examination

Conditions studied

Covid 19 — all drugs for Covid 19 →
BCG Vaccination — all drugs for BCG Vaccination →

Sponsor

Direction des Soins de Santé de Base

Who can join

Adults 18 to 80, any sex, with Covid 19 or BCG Vaccination. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Covid-19 In Tunisia: AN Observational Cross-Sectional Registry Study

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.
Flanagan KL, Best E, Crawford NW, Giles M, et al · · 2020 · cited 64× · PMID 33123165 · DOI 10.3389/fimmu.2020.579250
Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review.
Sohag AAM, Hannan MA, Rahman S, Hossain M, et al · · 2020 · cited 26× · PMID 32632960 · DOI 10.1002/ddr.21709
Convergence between global BCG vaccination and COVID-19 pandemic.
Islam MZ, Zahan MK, Al-Bari MAA. · · 2021 · cited 11× · PMID 32827313 · DOI 10.1002/jmv.26450
Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19.
Du J, Su Y, Wang R, Dong E, et al · · 2023 · cited 6× · PMID 36798128 · DOI 10.3389/fimmu.2023.1118378
What are the drugs having potential against COVID-19?
Kucukoglu K, Faydalı N, Bul D. · · 2020 · cited 4× · PMID 32929317 · DOI 10.1007/s00044-020-02625-1
Management of NMIBC during BCG shortage and COVID‐19
Mayor N, Fankhauser C, Sangar V, Mostafid H. · · 2021

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04384614 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Direction des Soins de Santé de Base
Last refreshed: 27 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04384614.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing